A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL

SIRPant-M (SI-101) - SIRPant Immunotherap

https://jitc.bmj.com/content/11/Suppl_1/A778

Koby Kidder1; Rita N Barcia1; Stephen Fogelson2; Candida Fratazzi3; Nathanael McCurley1

Sep 27, 2023